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Abstract
Background & Aims—The relationship between alcohol consumption and idiosyncratic drug 
induced liver injury (DILI) is not well understood. We investigated the relationship between heavy 
consumption of alcohol and characteristics and outcomes of patients with DILI enrolled in the 
Drug-induced Liver Injury Network (DILIN) prospective study.
Methods—We collected data from 1198 individuals with definite, highly likely, or probable DILI 
enrolled in the DILIN study from September 2004 through April 2016. At enrollment, all 
participants were asked about alcohol consumption; those with any alcohol consumption during 
previous 12 months were asked to complete the Skinner questionnaire to assess drinking history. 
Heavy consumption of alcohol was defined as more than 3 drinks, on average, per day by men or 
more than 2 drinks, on average, per day by women.
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Results—Of the 601 persons who reported consuming at least 1 alcoholic drink in the preceding 
12 months, 348 completed the Skinner questionnaire and 80 reported heavy consumption of 
alcohol. Heavy drinkers were younger (average age, 42 years) than non-drinkers (average age, 49 
years) and a higher proportion were men (63% of heavy drinkers vs 35% of nondrinkers) (P<.01 
for each comparison). Anabolic steroids were the most common cause of DILI among heavy 
drinkers (in 13% vs 2% in non-drinkers) (P<.001). Heavy drinkers had significantly higher peak 
serum levels of alanine aminotransferase (1323 U/L) than non-drinkers (754 U/L) (P=.02) and 
higher levels of bilirubin (16.1 mg/dL vs 12.7 mg/dL in non-drinkers) (P=.03) but there was no 
significant difference in liver-related death or liver transplantation between heavy drinkers 
(occurred in 10%) vs non-drinkers (occurred in 6%) (P=.18).
Conclusion—In an analysis of data from the DILIN, we found anabolic steroids to be the most 
common cause of DILI in individuals who are heavy consumers of alcohol. Compared to non-
drinkers, DILI was not associated with a greater proportion of liver-related deaths or liver 
transplantation in heavy drinkers.
Keywords
Drug Induced Liver Injury; Drug Induced Liver Injury Network; Significant alcohol consumption; 
RUCAM; Chronic DILI; ALT
Introduction
The relationship between alcohol consumption and acetaminophen hepatotoxicity is well 
recognized, but the relationship between alcohol consumption and other causes of drug 
induced liver injury (DILI) is less well defined (1,2). Alcohol consumption is one of the 
criteria in the RUCAM causality instrument for assessing liver injury (3,4), although there is 
no evidence that alcohol consumption increases the risk from medications other than 
methotrexate, isoniazid, antiretroviral agents, or halothane (5). Heavy alcohol consumption 
is believed to increase the risk of liver damage in individuals taking methotrexate long term 
(6,7). Chronic alcohol abuse may increase the risk of liver injury from anti-tuberculosis 
(anti-TB) agents (8,9), but not all studies have shown significant relationship between 
alcohol consumption and liver injury from anti-TB medications (10,11,12). The labeling for 
duloxetine, a frequently prescribed anti-depressant, recommends that individuals with 
substantial alcohol consumption should not take this medication (13), although there is no 
published evidence to support this recommendation. In an earlier study from the Drug 
Induced Liver Injury Network (DILIN), alcohol consumption, defined as any alcohol intake 
in the preceding 12 months, was unexpectedly associated with less severe injury in 
individuals with DILI (14).
To better understand the relationship between alcohol consumption and DILI, we 
investigated the relationship between heavy alcohol consumption and the causative agents, 
characteristics and outcomes of patients with DILI enrolled in the DILIN Prospective Study.
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Methods
Initiated in 2004, the DILIN Prospective Study (NCT00345930) enrolled individuals ≥ 2 
years old with suspected DILI at several clinical centers across the United States. The 
inclusion and exclusion criteria, evaluation for competing etiologies, follow-up, and 
causality and severity assessment have been described in previous publications (14–16). 
Several publications have resulted from the DILIN Prospective Study over the last decade, 
so that many participants included in this analysis were included in previous publications 
(17–21). The DILIN Prospective Study was approved by the Institutional Review Boards of 
the enrolling clinical centers and all participants provided written informed consent. In 
addition, the protocol and consent form were approved and the study monitored by an 
independent data and safety monitoring board appointed by the National Institutes of Health.
This analysis consisted of individuals enrolled between September 2004 and April 2016 who 
were judged to have definite, highly likely, or probable DILI. At the time of enrollment, 
participants were questioned about their alcohol consumption, and a trained interviewer 
administered a shortened version of the Skinner Alcohol Dependence Scale to individuals 
with any reported alcohol use within the preceding 12 months (22–24). This questionnaire 
obtained the following details of participants’ alcohol consumption history during five years 
before the DILI event: time and age range of alcohol consumption, drinks per day, drinking 
days per month, type of alcohol consumed, pattern of alcohol consumption (occasional, 
daily, weekend, binge), any life events influencing alcohol consumption, and perception of 
effect of alcohol consumption on their lives. For this analysis, heavy alcohol consumption 
was defined as regular average consumption of more than 2 drinks per for women and more 
than 3 drinks per day for men.
Statistics
Demographic and clinical data for subjects enrolled into the DILIN Prospective Study 
between September 2004 and April 2016 were extracted on September 9, 2016. Descriptive 
statistics, such as means with standard deviations, median with interquartile ranges and 
frequency distributions, were used to characterize the cohort. Differences between groups 
were tested using the χ2 test for categorical variables and Wilcoxon/Kruskal-Wallis test for 
the continuous variables. The primary outcomes of interest were (a) DILIN severity score, 
(b) liver transplantation or liver-related death, and (c) chronic DILI. Other outcomes of 
interest were severity of liver injury and causality assessment categories. Primary 
comparison was between individuals with heavy alcohol consumption and those without any 
alcohol consumption. Other comparisons were between (a) individuals with heavy drinking 
and those with non-heavy drinking and (b) individuals with and without any reported alcohol 
consumption. Statistical analyses were performed using SAS software, version 9.2 (SAS 
Institute, Cary, NC) and P values <0.05 were considered statistically significant, and P 
values between 0.05–0.10 were considered to show trends towards significance.
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Results
The DILIN Prospective Study enrolled 1723 participants between September 2004 and April 
2016 and 1512 had undergone six-month follow-up and causality adjudication before 
September 9, 2016. Of this total, 1198 participants were judged to have definite, highly 
likely, or probable DILI, and constituted the study cohort (Figure 1). At least some alcohol 
consumption was reported by 601 individuals while 597 reported no alcohol consumption in 
the preceding 12 months. The 601 participants were invited to complete the alcohol 
consumption questionnaire and 348 (58%) agreed. There were no significant differences in 
the demographics and clinical characteristics of individuals with reported consumption who 
did (n=348) and did not (n=253) complete the alcohol consumption questionnaire 
(Supplementary Table 1). Of 348 individuals who filled the alcohol consumption 
questionnaire, 80 individuals reported heavy consumption. The frequency of pre-existing 
liver disease was 11% in non-drinkers, 9% in non-heavy drinkers, and 11% in heavy 
drinkers (p=ns). The frequency of heavy drinking among individuals with DILI who had 
known pre-existing liver disease was 10.6%.
Comparison between individuals with heavy alcohol consumption and without any alcohol 
consumption
Compared to individuals with no alcohol consumption, participants with heavy consumption 
were younger (mean age 42 vs 49 years) and more likely men (52% vs 35%) but their self-
reported race and their body mass indices were not different (Table 1). Individuals with 
heavy alcohol consumption had lower frequency of diabetes mellitus (13% vs 28%, 
p=0.003), but the prevalence of preexisting liver disease was not different (11% in both 
groups). The latency to onset and the pattern of liver injury at presentation were similar 
between two groups. Individuals with heavy alcohol consumption had significantly higher 
peak serum ALT and total bilirubin levels but mean alkaline phosphatase or international 
normalized ratio (INR) values were similar as were the times to improvements in 
biochemical abnormalities.
The most commonly implicated therapeutic classes and specific agents are shown in Table 2. 
Interestingly, anabolic steroids were the most common cause of DILI in individuals with 
heavy alcohol consumption (13%) whereas they accounted few cases (2%) in those without 
alcohol consumption (p<0.001). Nevertheless, the overall characteristics (e.g., latency, 
pattern of liver injury, peak enzymes, pattern of recovery), severity and outcomes of liver 
injury due to anabolic steroids were not significantly different between individuals with 
heavy alcohol consumption (n=10) and those without alcohol consumption (n=12) (data not 
shown). The frequency of liver injury due to isoniazid was not different between two groups 
(6.3% in the heavy alcohol group vs. 5% in those without alcohol consumption, p=0.8).
Causality assessment and the proportion of cases judged to be definite vs highly likely vs 
possible were similar in the two groups (p=0.40, Table 3). While the overall distribution of 
severity scores were not different in the two groups, cases that were scored as severe or fatal 
were more frequent among those with heavy alcohol consumption compared to non-drinkers 
(36% vs 28%) as were numbers of death or liver transplantation (10% vs 6%, p=0.18), but 
these differences were not statistically significant (p=0.53). Finally, chronicity as defined as 
Dakhoul et al. Page 4
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
continued evidence of liver injury at 6 months after onset was similar in frequency between 
the two groups (18% vs 15%, p=0.53).
Comparison between individuals with heavy drinking and those with non-heavy drinking
Comparison of patients with mild or moderate alcohol intake to those with heavy 
consumption demonstrated similar differences to those comparing non-drinkers to heavy 
drinkers (Table 1 or 2) although the statistical significance of the differences were less, 
perhaps due to the fewer number of non-heavy drinkers. Thus, latency, pattern of liver injury 
and time to recovery among the 80 individuals with heavy alcohol consumption compared to 
the 268 individuals with non-heavy alcohol consumption were similar, but mean peak ALT, 
total bilirubin and INR values were higher in patients with heavy alcohol consumption 
(Tables 1 and 3). Subjects with heavy alcohol consumption had trends toward more severe 
liver injury with higher average DILIN severity scores (2.9 vs 2.6, p=0.06) but did not have 
higher likelihood of fatalities or liver transplantation (10% vs. 6.3%, p=0.27). Anabolic 
steroids were more frequently implicated in cases among those with heavy alcohol intake 
than those with less than heavy intake (13% vs 5%) (Table 2).
Comparison between individuals with and without any reported alcohol consumption
There were 601 individuals who reported any alcohol consumption whereas 597 consumed 
no alcohol in preceding 12 months (Supplemental Table 2). Their age and BMI were similar, 
but there were fewer women in individuals with alcohol consumption. Individuals with 
alcohol consumption had lower prevalence of diabetes mellitus but the prevalence of 
preexisting liver disease was similar between two groups. The frequency of liver injury due 
to herbal and dietary supplements was significantly higher in individuals with alcohol 
consumption than those without alcohol consumption (21.5% vs 14.4%, p<0.001). The 
latency between initiating the suspected agent and DILI recognition and the pattern of liver 
injury at presentation were similar between two groups. Compared to those without alcohol 
consumption, individuals with alcohol consumption had significant higher peak serum ALT 
values but lower INR. Interestingly, individuals with alcohol consumption had lower DILIN 
severity score compared to those without alcohol consumption (2.6 ± 1.2 vs.2.7 ± 1.2, 
p=0.032) but liver related death or need for liver transplantation (7% vs 6.2%, p=0.6) and 
chronic DILI (15.3% vs. 18.3%, p=0.2) were similar between two groups (Supplemental 
Table 2).
Alcohol Consumption and liver injury due to isoniazid
As it has been suggested that alcohol consumption is a possible risk factor for isoniazid 
hepatotoxicity, we examined if there was an association between alcohol consumption and 
isoniazid hepatotoxicity in our cohort. The proportion of liver injury attributed to isoniazid 
among heavy drinkers was 6.3% and it was not significantly different from non-drinkers 
(5%, p=0.6) or non-heavy drinkers (2.2%, p=0.13).
Death or Liver Transplantation among heavy drinkers with DILI
Two individuals with a history of heavy alcohol consumption died due to their liver injury 
and 6 others underwent liver transplantation for the acute liver injury (Table 4). The two 
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fatal cases consisted on a 44 year old Caucasian male with underlying alcoholic cirrhosis 
and steatohepatitis who developed acute on chronic liver failure 11 days after initiating 
niacin, and a 76 year old Caucasian male with chronic obstructive pulmonary disease who 
received azithromycin for a bronchitis flare and developed severe liver injury and skin rash 6 
days after initiating azithromycin, rapidly developing acute liver failure and dying 3 weeks 
later with multiorgan failure. Anti-HCV and HCV RNA were negative in all eight patients 
who died or received transplantation. Anti-HEV Ig G was negative in 6 patients and was 
positive in patients but without detectable anti-HEV Ig M. It appeared that 3 patients had 
underlying alcoholic liver disease and developed superimposed acute-on-chronic liver failure 
whereas five others developed acute liver failure to DILI without clinical evidence of 
preexisting alcoholic liver disease.
Analyses without individuals with probable DILI
When probable DILI cases were excluded, there were 445 non-drinkers, 205 non-heavy 
drinkers, and 63 heavy drinkers and their DILIN severity scores were 2.7 ± 1.2, 2.5 ± 1.1, 
and 2.9 ± 1.2 respectively. While there was no difference in the DILIN severity score 
between non-drinkers and heavy drinkers (p=0.33), it was significantly higher in heavy 
drinkers compared to non-heavy drinkers (p=0.03). There was no difference in liver-related 
deaths or liver transplantation (non-drinkers 4%, non-heavy drinkers 5.3%, and heavy 
drinkers 6.3% [p=0.33 vs. non-drinkers; p=0.75 vs non-heavy drinkers]), or chronic DILI 
(non-drinkers 15.9%, non-heavy drinkers 16.7%, and heavy drinkers 12.7% [p=0.55 vs. non-
drinkers; p=0.48 vs non-heavy drinkers].
Discussion
Although there is large body of literature investigating the role of alcohol consumption and 
acetaminophen hepatotoxicity, there is scant literature examining the relationship between 
alcohol consumption and idiosyncratic DILI. In this report we comprehensively examined 
the relationship between heavy and non-heavy alcohol consumption and causative agents, 
characteristics and outcomes of liver injury in a large cohort of prospectively enrolled 
patients with well characterized DILI. Our main observations are (a) DILI in individuals 
with heavy alcohol consumption did not necessarily result in significantly higher frequency 
of liver related deaths or required liver transplantation, compared to those without any 
alcohol consumption; (b) there was significant enrichment of anabolic steroid related liver 
injury in subjects with heavy alcohol consumption; and (c) individuals who reported any 
alcohol consumption tended to have lower DILIN severity score but their outcomes were not 
different from those who reported no alcohol consumption.
The higher frequency of liver injury due to anabolic steroids in patients with heavy alcohol 
consumption may simply represent a behavioral association rather than any 
pathophysiologic link between the two. These behaviors are more frequent in younger men. 
In a recent comprehensive literature review, Dodge and Hoagland observed a strong bivariate 
relationship between anabolic androgenic steroid abuse and alcohol use (25). The lifetime 
use of anabolic androgenic steroid use was positively associated with recent as well as 
lifetime alcohol use, problem/harmful drinking, and binge drinking (25). Nevertheless, our 
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study cannot exclude the possibility that heavy alcohol consumption increases the risk of 
developing liver injury caused by anabolic steroids.
The relationship between isoniazid hepatotoxicity and chronic alcohol consumption in the 
published literature has not been consistent. Some studies found significant association 
between chronic alcohol consumption and liver injury due to isoniazid or anti-tuberculosis 
drugs (8,9,26) whereas this relationship could not be demonstrated in other studies (10–12). 
In our study, liver injury due to isoniazid among individuals with heavy alcohol consumption 
was not more common than those with no alcohol consumption or mild to moderate alcohol 
consumption, but our study was not designed to specifically investigate alcohol consumption 
as a risk factor for isoniazid hepatotoxicity.
One of the instruments frequently used to adjudicate the causality in patients with suspected 
DILI is Roussel Uclaf Causality Assessment Method (RUCAM) and it is based on 7 
domains including age, alcohol, or pregnancy as risk factors (27). There is emerging 
consensus among the experts that alcohol consumption is not necessarily a risk factor for 
idiosyncratic DILI and arguably it should not be a criterion in assigning causality in 
suspected DILI (28). Although our study represents a detailed description of the relationship 
between DILI and alcohol consumption, because of it included only patients with suspected 
DILI it is not able to assess if alcohol consumption is a risk factor for DILI or its inclusion 
as one of the criteria in the RUCAM instrument.
Some aspects of our study design deserve further discussion. Our study consists of patients 
presenting to select clinical centers with well characterized DILI and thus it cannot address 
the causal relationship between alcohol consumption and all-cause DILI or liver injury 
caused by specific agents. Also, our study is based on self-reported alcohol use, which may 
underestimate the frequency and extent of alcohol consumption, but unfortunately there are 
no other practical methods to capture the details of alcohol consumption in studies of this 
nature. We also focus our discussion on the differences between non-drinkers and heavy 
drinkers where misclassification bias is probably lower. We had a significant number of 
patients that did not complete a Skinner questionnaire, but they did not differ significantly in 
terms of other clinical and demographic features. Counterbalancing these issues, are the 
DILIN’s unique strengths such as prospective study design, larger sample size, well 
characterized DILI phenotype and careful, structured adjudication of causality and severity.
In summary, anabolic steroids are the most common cause of DILI in individuals with heavy 
alcohol consumption. We did not find heavy alcohol consumption to be associated with 
worse outcomes in patients with DILI. Further, there was no evidence for heavy alcohol 
consumption as a risk factor for liver injury due to isoniazid in this experience.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Study Population: Flow Diagram
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